JVJosephine Volovetz

Josephine Volovetz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Josephine Volovetz has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Importance of Integrating Surgical Resection into Preclinical Glioblastoma Modeling

    by Josephine Volovetz, Line V. Buchwald, Karina Straede, Andreas Kjaer, Matthew Grabowski, Andrew Dhawan, Bjarne W. Kristensen, Justin D. Lathia

    Glioblastoma (GBM) remains a challenging tumor in terms of clinical management, with limited progress made since the standard of care was established in 2005. Maximal safe surgical resection, a cornerstone of the standard-of-care regimen, is a major determinant in patient outcome. However, this key clinical parameter is generally not accounted for in preclinical models, which are often used to provide a rationale for early-phase clinical trials. In this perspective, we cover the current types and status of preclinical GBM resection models and the insights they provide into the GBM disease process. In addition, we discuss how surgical resection alters the immune response, which can affect response to therapies, especially in the context of newly developing and contemporary immunotherapies. Given the complexity of GBM and the use of tumor resection in clinical management, we highlight the necessity and opportunity to integrate surgical resection into preclinical models to help inform and test the next generation of treatments.


  • Open Access

    STEM-15. SerpinB3 DRIVES CANCER STEM CELL SURVIVAL IN GLIOBLASTOMA

    by Adam Lauko, Soumya M Turaga, Josephine Volovetz, Defne Bayik, Shideng Bao, Jennifer Yu, Justin Lathia

    Despite therapeutic interventions for glioblastoma (GBM), self-renewing, therapy-resistant populations of cells referred to as cancer stem cells (CSCs) drive recurrence. Previously, we identified the unique expression of junctional adhesion molecule-A (JAM-A) on CSCs and demonstrated that JAM-A is both necessary and sufficient for self-renewal and tumor growth. Moreover, we determined that JAM-A signals via Akt in GBM CSCs to sustain pluripotency transcription factor activity; however, the entire signaling network has yet to be fully elucidated. To further delineate this pathway, we immunoprecipitated JAM-A from patient-derived GBM CSCs and performed mass spectrometry to determine JAM-A binding proteins. This led to the identification of the cysteine protease inhibitor SerpinB3 as a putative JAM-A binding partner. Using in vitro CSC functional assays, we show that SerpinB3 is necessary for CSC maintenance and survival. In an in vivo orthotopic xenograft model, knockdown of SerpinB3 extended survival. Mechanistically, knockdown of SerpinB3 led to decreased expression of TGF-β, Myc, WNT, and Notch signaling, known regulators of the CSC state. Additionally, knockdown of SerpinB3 increases susceptibility to radiation therapy. SerpinB3 is essential for buffering cells against cathepsin-mediated cell death, and we found that elevated lysosomal membrane permeability after radiation leads to cathepsin release into the cytoplasm. As a result, SerpinB3 knockdown cells have a diminished capacity to inhibit cathepsin-driven cell death after radiation. The addition of the cathepsin inhibitor E64D partially rescues the SerpinB3 knockdown, however, SerpinB3 mutants that are unable to inhibit cathepsins fail to do the same. Taken together, our findings, identify a novel GBM CSC-specific survival mechanism involving a previously uninvestigated cysteine protease inhibitor, SerpinB3, and provide a potential target to increase the efficacy of standard of care GBM therapies against therapy-resistant CSCs.

  • Open Access

    STEM-07. IDENTIFICATION OF A NOVEL CSC SIGNALING AXIS CONTAINING JAM-A/SERPINB3/TGF-BETA

    by Adam Lauko, Soumya Turaga, Josephine Volovetz, Defne Bayik, Ulhas Naik, Justin Lathia

    Despite therapeutic interventions including surgery, radiation, and chemotherapy, multiple clones of treatment resistant cells repopulate the tumor, resulting in recurrence and a high rate of mortality in glioblastoma. Effective targeting of these cancer stem cells (CSCs) has been limited by our incomplete understanding of the intracellular signaling mechanisms maintaining the CSC state. Our laboratory previously identified junctional adhesion molecule-A (JAM-A) on CSCs and, through functional studies, demonstrated that JAM-A is both necessary and sufficient for self-renewal and tumor growth. We determined that JAM-A signals via Akt in GBM CSCs to sustain pluripotency transcription factor activity; however, the intermediate signaling network is yet to be fully elucidated. Therefore, our goal was to delineate the pathway downstream of JAM-A. To achieve this, we immunoprecipitated JAM-A from GBM CSCs and performed mass spectrometry leading to the identification of the serine/cysteine protease inhibitor SerpinB3. While SerpinB3 has a functional role in lung adenocarcinoma, breast, pancreas, as well as in hepatocellular carcinoma, there is limited information in GBM or CSCs, and its relationship to JAM-A is yet to be elucidated. Using in vitro CSC functional assays, we observed that SerpinB3 is necessary for the maintenance of CSCs. Additionally, in an intracranial implantation model of GBM the knockdown of SerpinB3 extended the survival of mice. Knockdown of SerpinB3 in multiple GBM CSCs models also led to decreased expression of TGF-β, a known regulator of the CSC state. We also observed that SerpinB3 stabilizes JAM-A expression and further studies are investigating the mechanism of this stabilization, identifying the specific interaction sites of JAM-A and Serpin B3, and determining how TGF-β alters the association through positive and negative feedback mechanisms. Taken together, these data highlight the role of SerpinB3 in GBM CSCs and provides a novel target to inhibit the JAM-A-mediated CSC maintenance as a next-generation GBM therapy.

  • Association Between Blood Alcohol Content and Outcomes After Traumatic Spinal Cord Injury

    by Mary Jo Roach, Josephine Volovetz, Michael Kelly, Argyrios Stampas

  • Open Access

    Reply—Acknowledging Intersectionality and Historical Context in Medical Education Research

    by Alexander Chaitoff, Josephine Volovetz, Blair Mitchell-Handley

  • Origin and development of oligodendroglioma

    by Josephine Volovetz, Defne Bayik, Justin D. Lathia

  • Esthesioneuroblastoma: Descriptive Epidemiology from the Central Brain Tumor Registry of the United States

    by Samantha Colby, Jaes Jones, Ghaith Habboub, Alex Witek, Shahed Tish, Josephine Volovetz, Paramita Das, Quinn T. Ostrom, Carol Kruchko, Jill S. Barnholtz-Sloan, et al.

    Introduction: Esthesioneuroblastoma, also referred to as olfactory neuroblastoma, is a rare malignant neoplasm arising from olfactory neuroepithelium. Aiming to provide a comprehensive epidemiologic analysis of esthesioneuroblastomas, this study draws from the Central Brain Tumor Registry of the United States (CBTRUS), which contains population-based incidence data covering 99% of the United States population from 1994 to 2014. Methods: CBTRUS was queried for esthesioneuroblastomas based on ICD-O-3 codes. Age-adjusted incidence per 100,000 persons was calculated and stratified by race, sex, age, lesion location, and diagnostic method. Joinpoint Regression Program was used to calculate annual percentage change in incidence rates over time. Results: A total of 2,103 esthesioneuroblastomas were diagnosed in the United States from 2001 to 2014, averaging ∼150 cases annually. The most common location was the nasal cavity (1709 cases). Those not located in the nasal cavity were found in the ethmoid (182 cases), sphenoid (50 cases), maxillary (39 cases), or accessory sinuses (68 cases). Overall age-adjusted rate was 0.0477 per 100,000 (95% CI, 0.0457–0.0498). There was no statistically significant change in annual rates from 2001 to 2014. A peak rate of 0.1331 per 100,000 (95% CI, 0.1118–0.1571) occurred in patients aged 75–79 years. The rate in males (0.0587 per 100,000; 95% CI, 0.0555–0.0622) was significantly higher (p < 0.05) than in females (0.0013 per 100,000; 95% CI, 0.0354–0.0406). The rate was highest in non-Hispanic white patients at 0.0495 per 100,000 (95% CI, 0.0472–0.0519). The rate ratio of esthesioneuroblastoma in black patients to non-Hispanic white patients was 0.6452 (p < 0.05). There were not enough American Indian/Alaska Native patients to form definitive conclusions. Conclusion: The incidence of esthesioneuroblastomas was higher in males relative to females, and in non-Hispanic white patients relative to black patients. Incidence peaked in patients aged 75 to 79 years. This study represents the most comprehensive epidemiological analysis of esthesioneuroblastoma incidence rate in the United States to date.

  • Open Access

    IMMU-70. GLOBAL IMMUNE FINGERPRINTING IN GLIOBLASTOMA REVEALS IMMUNE-SUPPRESSION SIGNATURES ASSOCIATED WITH PROGNOSIS

    by Tyler Alban, Alvaro Alvarado, Mia Sorensen, Defne Bayik, Josephine Volovetz, Emily Serbinowski, Erin Mulkearns-Hubert, Maksim Sinyuk, James Hale, Giovana Onzi, et al.

    Therapeutic resistance in glioblastoma (GBM) is linked to cancer stem cells and signaling pathway alterations, but the role of local and systemic immune suppression during disease progression is less understood. To determine how the immune system as a whole is altered in GBM patients, a CyTOF panel of 25 immune markers was developed for immune fingerprinting of peripheral blood mononuclear cells (PBMCs). CyTOF analysis was performed on select patients with either favorable or poor prognosis from a cohort of newly diagnosed GBM patients, from whom PBMCs were collected throughout disease progression. Multi-dimensional cluster analysis identified a reduction of Monocytic Myeloid-Derived Suppressor Cells (M-MDSCs) in the patient with favorable prognosis, while the patient with poor prognosis had higher levels of M-MDSCs. Additionally, when LGG patients were compared to GBM patients, LGG patients had more Dendritic cells and Natural Killer cells as compared to GBM patients. To understand whether this elevation in MDSC was unique to GBM or whether MDSCs were high across primary and secondary brain tumors, a cohort of 259 patient PBMC samples was analyzed. GBM patients had a significant elevation in MDSCs in blood, but not immunosuppressive T regulatory cells as compared to non-malignant brain tumors. To determine whether MDSCs in the GBM microenvironment also correlate with survival, a cohort of patients with matched primary and secondary resections were analyzed for MDSCs by immunofluorescence, which determined that intra-tumoral MDSCs correlate with poor prognosis in recurrent samples, while general myeloid infiltration correlated with a good prognosis. These studies identify low MDSC immune signatures that are linked to enhanced pro-inflammatory cells and overlap between GBM patients with a good prognosis and LGG patients, promoting the idea of targeting MDSCs in GBM patients to alter their immune status to that of a lower grade tumor.

  • Open Access

    STEM-24. IDENTIFICATION OF SERPIN B3 AS A JUNCTIONAL ADHESION MOLECULE A BINDING PARTNER IN GLIOBLASTOMA CANCER STEM CELLS

    by Josephine Volovetz, Soumya Turaga, Ulhas Naik, Justin Lathia

    Cancer stem cells (CSCs) in glioblastoma (GBM), the most lethal primary brain tumor, contribute to tumor progression and therapeutic resistance. While we previously demonstrated that junctional adhesion molecule A (JAM-A), a cell adhesion molecule, is necessary and sufficient for CSC maintenance, the signaling networks underlying this function have yet to be elucidated. JAM-A has several known binding partners in endothelial cells. To identify GBM CSC-specific binding partners, we introduced JAM-A into CSCs, conducted a pull-down assay, and determined binding partners via mass spectrometry. The top candidate identified was Serpin B3, a serine/cysteine proteinase inhibitor and key regulator of epithelial to mesenchymal transition. We validated the endogenous interaction between JAM-A and Serpin B3 via co-immunoprecipitation and confirmed binding dynamics in vitro via surface plasmon resonance. Like JAM-A, Serpin B3 was enriched in CSC patient-derived xenograft models. Immunostaining revealed colocalization of Serpin B3 and JAM-A, in vitro and in vivo. Overexpression of Serpin B3 was found to increase stem cell marker expression. Ongoing studies are assessing proliferation, self-renewal, and tumor initiation in the context of Serpin B3 overexpression in non-CSCs and Serpin B3 knockdown in CSCs. Additional mechanistic studies using JAM-A mutant constructs will determine the precise binding site between JAM-A and Serpin B3 and serve as the basis for developing therapeutics that inhibit the interaction between JAM-A and Serpin B3. Our findings provide a novel JAM-A binding partner and reveal a putative interaction that may be disrupted to compromise CSC maintenance.

  • Open Access

    Mortality in Pituitary Adenoma Surgery in Teaching versus Nonteaching Hospitals

    by Josephine Volovetz, Min Lang, Lu Dai, Ghaith Habboub, Paramita Das, Shahed Tish, Jaes Jones, Samantha Colby, Varun R. Kshettry, Pablo F. Recinos

    Background Pituitary adenomas are among the most common tumors of the central nervous system. Surgical resection is the first-line treatment option for symptomatic pituitary adenomas and for non-prolactinoma functional tumors. Resections are performed at both teaching and nonteaching hospitals across the country. Given differences between the hospitals, with medical education playing a role in teaching hospitals, there is a question of whether or not there is a difference in quality of care for pituitary adenoma resection patients. Outcomes after pituitary adenoma resection between the two types of hospitals have not previously been studied. Methods A retrospective study was performed of the Nationwide Inpatient Sample, a database of hospital admissions from more than 1,000 hospitals, between the years 2006 and 2011. Teaching and nonteaching hospital admissions for elective pituitary adenoma resection in patients ≥18 years old were included for analysis. Teaching hospitals are defined as those with an AMA-approved residency training program, those with membership in the Council of Teaching Hospitals, or those with a ratio of full-time interns and residents to beds of 1:4 or higher. Analysis between the two types of hospitals included a comparison of patient characteristics, including likelihood of dying and illness severity. The primary outcome explored was inpatient mortality, and the secondary outcome was length of stay. Results A total of 7,826 admissions from teaching hospitals and 1,618 admissions from nonteaching hospitals were compared. The median age and the proportion of females between the two patient populations had a statistically but not clinically significant difference. The illness severity and likelihood of dying of the patients in teaching hospitals compared with nonteaching hospitals were significantly different (p = 0.004 and p = 0.005, respectively), with more patients in nonteaching hospitals having an “extreme” severity of illness ranking and an “extreme” likelihood of dying ranking. In terms of comorbidities potentially associated with the pituitary adenoma, there were significantly more patients with hypothyroidism in teaching hospitals than in nonteaching hospitals (p = 0.028). No significant difference was seen in hospital deaths between the two groups, while a statistically but not clinically significant difference in length of stay was seen between the two (p < 0.001). Conclusion No significant difference in inpatient mortality after pituitary adenoma resection was found between teaching and nonteaching hospitals, although there may be a difference between the level of comorbidities of patients undergoing resection in teaching and nonteaching hospitals.